查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1671137

骨髓恶性肿瘤治疗药的全球市场:市场规模·占有率·趋势，产业分析 (各疾病·各治疗法·各最终用途·各地区)，未来预测 (2025年～2034年)

Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，血液系统恶性肿瘤药物市场预计到 2034 年将达到 1,481.5 亿美元。该报告提供了有关当前市场动态的详细见解，并对未来市场的成长进行了分析。

血液系统恶性肿瘤药物是指用于治疗血癌的疗法，包括白血病、淋巴瘤和骨髓瘤。这些癌症会影响血液、骨髓、淋巴系统和脾臟，需要专门的治疗方法。受白血病、淋巴瘤、骨髓瘤等血癌发病率不断上升以及治疗方案不断改进的推动，血液系统恶性肿瘤药物的市场占有率正在显着增长。主要推动因素包括CAR-T细胞疗法和单株抗体等免疫疗法的兴起，以及提供更精准治疗且副作用更少的标靶疗法的日益普及。联合疗法、个人化医疗和生物相似药的推广也带来了机遇，这些疗法为传统治疗提供了具有成本效益的替代方案。此外，正在进行的研究、临床试验和新疗法的监管批准继续推动市场创新。透过转向门诊治疗来改善患者就医机会以及注重减少治疗抵抗等趋势正在促进市场的整体扩张，预计未来几年市场将继续增长。

血液系统恶性肿瘤药物市场：分析概述

由于慢性淋巴细胞白血病 (CLL) 和急性髓细胞白血病 (AML) 等疾病的发生率很高，白血病在市场占有率方面占据主导地位。标靶治疗的重大进展正在推动成长。然而，由于 CAR-T 细胞疗法等免疫疗法的采用日益广泛，淋巴瘤成为成长最快的领域。

免疫疗法占据血液系统恶性肿瘤治疗市场的最大占有率，其中CAR-T细胞疗法和单株抗体在改变血液系统恶性肿瘤治疗方面发挥关键作用。随着精准医疗不断改善血癌患者的治疗效果并减少副作用，标靶治疗正在实现最快的成长。

医院药房占据了最大的市场占有率，因为它们在提供 CAR-T 细胞疗法和化疗等复杂治疗方面发挥着核心作用。零售药局是成长最快的领域，这得益于对口服溶瘤药物和家庭治疗方案的需求不断增长。

北美因其较高的治疗可及性、先进的医疗基础设施以及对新疗法的监管支持而占据市场主导地位。由于癌症发生率的增加、医疗保健机会的改善以及对治疗创新的投资，亚太地区是成长最快的地区。

目录

第1章 简介

第2章 摘要整理

第3章 分析方法

第4章 骨髓恶性肿瘤治疗药市场洞察

  • 市场概述
  • 骨髓恶性肿瘤治疗药的市场动态
    • 促进因素和机会
      • 整合人工智慧与机器学习
      • 过渡到高通量实验
    • 阻碍因素与课题
      • 资料数量的不足
  • 大环境分析
  • 骨髓恶性肿瘤治疗药市场趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球骨髓恶性肿瘤治疗药市场:各疾病

  • 主要的分析结果
  • 简介
  • 白血病
  • 淋巴瘤
  • 骨髓瘤

第6章 全球骨髓恶性肿瘤治疗药市场:各治疗法

  • 主要的分析结果
  • 简介
  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 其他

第7章 全球骨髓恶性肿瘤治疗药市场:各最终用途

  • 主要的分析结果
  • 简介
  • 医院药局
  • 其他

第8章 全球骨髓恶性肿瘤治疗药市场:各地区

  • 主要的分析结果
  • 简介
    • 骨髓恶性肿瘤治疗药市场评估:各地区 (2020～2034年)
  • 北美
    • 北美:疾病 (2020～2034年)
    • 北美:各治疗法 (2020～2034年)
    • 北美:各最终用途 (2020～2034年)
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:疾病 (2020～2034年)
    • 欧洲:各治疗法 (2020～2034年)
    • 欧洲:各最终用途 (2020～2034年)
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:疾病 (2020～2034年)
    • 亚太地区:各治疗法 (2020～2034年)
    • 亚太地区:各最终用途 (2020～2034年)
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:疾病 (2020～2034年)
    • 中东·非洲:各治疗法 (2020～2034年)
    • 中东·非洲:各最终用途 (2020～2034年)
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东·非洲
  • 南美
    • 南美:疾病 (2020～2034年)
    • 南美:各治疗法 (2020～2034年)
    • 南美:各最终用途 (2020～2034年)
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 事业扩大·企业收购的分析
    • 事业扩大
    • 企业收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • BeiGene
  • Kite Pharma(a subsidiary of Gilead Sciences)
  • Celgene Corporation(acquired by Bristol-Myers Squibb)
  • Regeneron Pharmaceuticals, Inc.
Product Code: PM1347

The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.

Hematologic Malignancies Therapeutics Market Report Highlights

Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.

Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.

Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.

North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.

Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

  • Leukemia
  • Lymphoma
  • Myeloma

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Others

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hematologic Malignancies Therapeutics Market Insights

  • 4.1. Hematologic Malignancies Therapeutics Market - Market Snapshot
  • 4.2. Hematologic Malignancies Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Integration of AI and Machine Learning
      • 4.2.1.2. Shift Toward High-Throughput Experimentation
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Insufficient data volume
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hematologic Malignancies Therapeutics Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hematologic Malignancies Therapeutics Market, by Disease

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • 5.3. Leukemia
    • 5.3.1. Global Hematologic Malignancies Therapeutics Market, by Leukemia, by Region, 2020-2034 (USD Billion)
  • 5.4. Lymphoma
    • 5.4.1. Global Hematologic Malignancies Therapeutics Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
  • 5.5. Myeloma
    • 5.5.1. Global Hematologic Malignancies Therapeutics Market, by Myeloma, by Region, 2020-2034 (USD Billion)

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Hematologic Malignancies Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Hematologic Malignancies Therapeutics Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 6.5. Targeted Therapy
    • 6.5.1. Global Hematologic Malignancies Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Hematologic Malignancies Therapeutics Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hematologic Malignancies Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Others
    • 7.4.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Hematologic Malignancies Therapeutics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hematologic Malignancies Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Hematologic Malignancies Therapeutics Market - North America
    • 8.3.1. North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Hematologic Malignancies Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Hematologic Malignancies Therapeutics Market - Canada
      • 8.3.5.1. Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Hematologic Malignancies Therapeutics Market - Europe
    • 8.4.1. Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Hematologic Malignancies Therapeutics Market - UK
      • 8.4.4.1. UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Hematologic Malignancies Therapeutics Market - France
      • 8.4.5.1. France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Hematologic Malignancies Therapeutics Market - Germany
      • 8.4.6.1. Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Hematologic Malignancies Therapeutics Market - Italy
      • 8.4.7.1. Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Hematologic Malignancies Therapeutics Market - Spain
      • 8.4.8.1. Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Hematologic Malignancies Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Hematologic Malignancies Therapeutics Market - Russia
      • 8.4.10.1. Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Hematologic Malignancies Therapeutics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Hematologic Malignancies Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Hematologic Malignancies Therapeutics Market - China
      • 8.5.4.1. China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Hematologic Malignancies Therapeutics Market - India
      • 8.5.5.1. India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Hematologic Malignancies Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Hematologic Malignancies Therapeutics Market - Japan
      • 8.5.7.1. Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Hematologic Malignancies Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Hematologic Malignancies Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Hematologic Malignancies Therapeutics Market - Australia
      • 8.5.10.1. Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Hematologic Malignancies Therapeutics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Hematologic Malignancies Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Hematologic Malignancies Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Hematologic Malignancies Therapeutics Market - UAE
      • 8.6.5.1. UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Hematologic Malignancies Therapeutics Market - Israel
      • 8.6.6.1. Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Hematologic Malignancies Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Hematologic Malignancies Therapeutics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Hematologic Malignancies Therapeutics Market - Latin America
    • 8.7.1. Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Hematologic Malignancies Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Hematologic Malignancies Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Hematologic Malignancies Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Hematologic Malignancies Therapeutics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Amgen Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Gilead Sciences Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck & Co., Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. AstraZeneca
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. BeiGene
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kite Pharma (a subsidiary of Gilead Sciences)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Celgene Corporation (acquired by Bristol-Myers Squibb)
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Regeneron Pharmaceuticals, Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 2 Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 3 Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 4 North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 5 North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 6 North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 8 U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 9 U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 10 Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 11 Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 12 Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 14 Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 15 Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 16 UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 17 UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 18 UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 20 France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 21 France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 22 Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 23 Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 24 Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 26 Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 27 Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 28 Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 29 Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 30 Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 34 Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 35 Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 36 Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 44 China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 45 China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 46 India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 47 India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 48 India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 52 Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 53 Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 54 Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 58 South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 59 South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 60 South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 62 Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 63 Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 73 UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 74 UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 75 UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 76 Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 77 Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 78 Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 79 South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 80 South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 81 South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 85 Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 86 Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 87 Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 88 Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 89 Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 90 Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 91 Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 92 Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 93 Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 94 Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 95 Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 96 Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Hematologic Malignancies Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease
  • Figure 7. Global Hematologic Malignancies Therapeutics Market, by Disease, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy
  • Figure 9. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2024 & 2034 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Hematologic Malignancies Therapeutics Market, by End Use, 2024 & 2034 (USD Billion)